Key clinical point: Decision making for elder patients with MM should include a discussion of the burden of care, not just possible outcomes.
Major finding: There is substantial burden of treatment, with over 2 months of cumulative interaction with health care in the first year.
Study details: The treatment burden among 3,065 newly diagnosed adults with MM was retrospectively analyzed.
Disclosures: The study was funded by the National Cancer Institute at the U.S. National Institutes of Health. The authors reported funding from a variety of pharmaceutical and biotechnology companies.
Mian HS et al. Clin Lymphoma Myeloma Leuk. 2020 Oct 1. doi: 10.1016/j.clml.2020.09.010.